Oncaspar European Union - English - EMA (European Medicines Agency)

oncaspar

les laboratoires servier - pegaspargase - precursor cell lymphoblastic leukemia-lymphoma - antineoplastic agents, - oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (all) in paediatric patients from birth to 18 years, and adult patients.,

Mastergraft Putty - Bone implant material, biological, animal-source Australia - English - Department of Health (Therapeutic Goods Administration)

mastergraft putty - bone implant material, biological, animal-source

medtronic australasia pty ltd - 46425 - bone matrix implant, animal-derived, bioabsorbable - mastergraft? putty is supplied as a sterile, dry, solid, construct that is hydrated for single patient use and is a mouldable form of bone void filler. mastergraft? products are biocompatible, osteoconductive, porous implants that allows for bony in growth across the graft site while resorbing at a rate consistent with bone healing. mastergraft? putty is intended to help fill voids or gaps in bone, which may be surgically created osseous defects, or osseous defects caused by traumatic injury to the bone. mastergraft? putty provides a bone void filler that is resorbed and is replaced with bone during the natural healing process. the putty when combined with either autogenous bone marrow, and/or sterile water, and/or autograft is indicated as a bone void filler for bony voids or gaps that are not intrinsic to the stability of the bony structure. additionally, mastergraft putty can be used with autograft as a bone extender. specific indications for use include oral/maxillofacial augmentation or reconstruction.